Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘BRAF V600 mutations’

With all the furore surrounding the new developments with KRAS G12C inhibitors in lung and colon cancer, it is easy to forget that there are plenty of other promising related ideas in the pipeline too. After all, there’s more than one KRAS mutation that can act as an oncogenic driver in patients that can portend poorer prognosis.

Aside from the obvious small molecules, there are other modalities to consider.

Here’s one such novel design that caught our attention — it has the potential to be elevated into an elegant platform approach with different molecules targeting a variety of critical mutations in tumour cells including KRAS G12D, which is prevalent in colon and pancreatic cancers.

I’ve had my eye on this work for a couple of years and now it’s a good time to showcase it in the spotlight given the sheer energy and attention focused on this niche…

To learn more from our oncology coverage and get a heads up on insights from our latest thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

The many faces of lung cancer requires an appreciation of nuance in treatment

Barcelona – Many observers seem to so be single mindedly focused on immunotherapies of late that they may well be forgiven that, hey, there’s still much going on the world of targeted therapies!

If there is one thing we can learn from the lung cancer (and CML) communities it is their dedication to identifying resistance mechanisms and along with them, novel targets for subsequent therapy in order to set about improving outcomes for people with the disease.

As a result, lung cancer can now be segmented into many subsets, each requiring careful consideration of appropriate therapy options, not only in newly diagnosed disease, but also what to do with subsequent lines of therapy.

In this review, our third from the WCLC 2019 meeting, we pull together a lot of disparate loose ends on targeted therapies and draw some important themes together…

To learn more from our latest oncology conference insights and get a heads up on the evolving science and resistance mechanisms, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

It’s time for the August mailbag where we answer questions about cancer research and R&D from subscribers.

After the recent queries about immuno-oncology, it’s time to focus a little on targeted therapies again. Neither chemotherapies nor targeted therapies are going to go away – they are still the bedrock of many treatment approaches in the clinic today. Sadly though, much of the new data for the latter trials were easily swamped by the sheer tsunami of immunotherapy data in Philadelphia (AACR) and Chicago (ASCO).

One important area that we have been discussing on both blogs for some time is the value of well designed basket trials.  It’s time to revisit this concept in the light of new data relating to the BRAF V600 mutation outside of metastatic melanoma.

To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content. 

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!